Rank #1557SGMO

Sangamo Therapeutics, Inc.

$0.38

4.77% (Daily)

Market Cap

$141.20M

Revenue

$32.88M

Rank by MCap

#1557

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.

Headquarters

Richmond, CA

Employees

183

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is ...